Gardiquimod

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Gardiquimod 

Gardiquimod，一种咪唑啉类似物，TLR7/8 激动剂。Gardiquimod 可抑制巨噬细胞和活化外周血单个核细胞 (PBMCs) 的 HIV-1 感染。当浓度低于 10 μM 时，Gardiquimod 特别激活 TLR7。

Gardiquimod

Gardiquimod Chemical Structure

CAS No. : 1020412-43-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Gardiquimod 的其他形式现货产品:

Gardiquimod diTFA

生物活性

Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10 μM[1][2].

IC50 & Target[1]

TLR7

 

TLR8

 

HIV-1

 

体外研究
(In Vitro)

Gardiquimod (6-60 μM ) significantly inhibits cDNA synthesis by HIV-1 reverse transcriptase[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Dendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) improves the anti-tumor effects of NK cells[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)[2]
Dosage: 1 mg/kg per mouse
Administration: i.p.; daily for 7 days
Result: Significantly suppressed the growth of human HepG2 liver carcinoma xenografts.

分子量

313.40

Formula

C17H23N5O
CAS 号

1020412-43-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18.

    [2]. Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务